Novartis v Sun Pharmaceutical: a battle over second medical use patents

19-02-2016

Michiel Rijsdijk

In Europe, it is well established that a second medical use patent can be obtained for any second or further therapeutic use of a known drug, providing the use is novel and inventive. However, a recent judgment in the Netherlands highlights that this is a developing area of law, and that there is uncertainty.


Michiel Rijsdijk, Arnold + Siedsma, medical use patent, patent, Novartis, Paget disease,

WIPR